pfizer glp-1 drug Safety worries spur to drop another obesity pill Pfizer moves forward with weight-loss

Allulose is not a GLP-1 agonist, but emerging research suggests it may modulate glucose metabolism and GLP-1 secretion in ways that merit clinical attention

The global obesity treatment market is expanding at unprecedented speed, with sales of weight-loss medications forecast to rise dramatically over the next decade.

Those with obesity might have other serious chronic health conditions, including diabetes and high blood pressure, which are leading risk factors for heart disease and stroke

Semaglutide: Tirzepatide is a dual agonist for GLP-1 and GIP receptors

Effectiveness and Impact Significant Weight Loss: Phase 2 studies showed up to roughly 20% average body weight loss at 52 weeks in participants with obesity

A summary of the guidelines for perioperative management of GLP-1 RAs, GIP agonists, & SGLT2 inhibitors in adults.